Menu
← Oncology Approval Tracker
FDA DECISION ·
Ennumo
pegfilgrastim-pccg · Accord BioPharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Neulasta biosimilar for lowering infection risk manifested by febrile neutropenia in patients with nonmyeloid cancers receiving myelosuppressive anticancer drugs associated with a clinically significant risk of febrile neutropenia.
LAMPGEN ANALYSIS
Why it matters
This adds a supportive-care option for an established growth-factor use. Site-level sourcing and coverage affect whether another approved option improves access.
What research teams should watch
Coordinate injection timing with chemotherapy and keep the actual product documented. Verify the device and presentation before assuming workflow equivalence.
PRIMARY RECORDS